You have access
Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer
KOICHI SAKAGUCHI, KATSUHIKO NAKATSUKASA, HIROSHI KOYAMA, MAKOTO KATO, AKIRA SAKUYAMA, TAKAYUKI MATSUDA, NOBUYUKI TSUNODA, IKUYA FUJIWARA, MASAHIDE YAMAGUCHI, HIROKI TANAKA, KAZUYOSHI ONISHI, MIE ONISHI, YUJI YOSHINO, TAKASHI KIKUCHI and TETSUYA TAGUCHI
Anticancer Research July 2018, 38 (7) 4073-4081; DOI: https://doi.org/10.21873/anticanres.12697